TRINOMIA 20mg + 100mg + 5mg Kapsula, tvrda Montenegro - croato - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

trinomia 20mg + 100mg + 5mg kapsula, tvrda

amicus pharma doo podgorica - atorvastatin, acetilsalicilna kiselina, ramipril - kapsula, tvrda - 20mg + 100mg + 5mg

TRINOMIA 20mg + 100mg + 10mg Kapsula, tvrda Montenegro - croato - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

trinomia 20mg + 100mg + 10mg kapsula, tvrda

amicus pharma doo podgorica - atorvastatin, acetilsalicilna kiselina, ramipril - kapsula, tvrda - 20mg + 100mg + 10mg

DUOPLAVIN 75 mg/1 tableta+ 100 mg/1 tableta film tableta Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

duoplavin 75 mg/1 tableta+ 100 mg/1 tableta film tableta

amicus pharma d.o.o. - acetilsalicilna kiselina, klopidogrel - film tableta - 75 mg/1 tableta+ 100 mg/1 tableta - 1 film tableta sadrži: 75 mg klopidogrela (u obliku klopidogrelhidrogensulfata) i 100 mg acetilsalicilne kiseline

STARTINA 5 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 5 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 5 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 5 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

STARTINA 10 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 10 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 10 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 10 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

STARTINA 20 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda Bosnia Erzegovina - croato - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

startina 20 mg/1 kapsula+ 100 mg/1 kapsula kapsula, tvrda

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetilsalicilna kiselina, rosuvastatin - kapsula, tvrda - 20 mg/1 kapsula+ 100 mg/1 kapsula - 1 kapsula, tvrda sadrži 20 mg rosuvastatina (u obliku rosuvastatinkalcijuma) i 100 mg acetilsalicilne kiseline

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Unione Europea - croato - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Plavix Unione Europea - croato - EMA (European Medicines Agency)

plavix

sanofi winthrop industrie - klopidogrel hidrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. sprječavanje атеротромботических i тромбоэмболических događaja kada фибрилляции fibrillationin odraslih pacijenata s фибрилляцией vrlo značajan, koje imaju najmanje jedan faktor rizika za razvoj srčanih događaja, nisu pogodni za liječenje vitamin-k-antagonisti i koji imaju nizak rizik od krvarenja, клопидогрел prikazan u kombinaciji s ask za prevenciju атеротромботических i тромбоэмболических događaja, uključujući i moždani udar.